Skip to main content Skip to main content

Peptide Dosages | DosageFacts

Peptide dosage reference for the US and Canada
DOSAGEFACTS

HomePeptide dosagesSLU-PP-332

SLU-PP-332 dosage: what is known

There is no human dose for SLU-PP-332. It has not been given to people in any published or registered study. The lab that made it injected it into mice and reports that it is poorly absorbed by mouth. It is a small molecule, not a peptide, and it is not approved.

Last checked 10 Oct 2026Sources 12 checkedChange log

Legal status

US Not approved

Canada Not authorized

Checked 10 Oct 2026What is SLU-PP-332?

SLU-PP-332 dose

No human dose

No human studies of SLU-PP-332 have been published. The only dosing on record is in mice, so there is no dose table here.

What people report using

Peer reports. Not medical or scientific advice.

HowAmount people reportPattern people report
By mouth100 to 800 mcg a dayin 1 to 3 doses
By injection250 mcg to 1.5 mg a dayfor example 8 weeks on, 8 weeks off

These are amounts users describe online, taken from Google AI Overview for the search 'what are known SLU-PP-332 protocols' on 11 Oct 2026. No human study has tested them, no doctor or regulator has checked them, and they are not a recommendation. They are here so you know what is being passed around. How much of a dose taken by mouth is absorbed in people has not been studied.

What SLU-PP-332 is

SLU-PP-332 is a synthetic small molecule that switches on the estrogen-related receptors ERR alpha, beta and gamma. It is not a peptide. It has been studied in cells and mice as a compound that copies some effects of exercise. [1]

Other names: (E)-4-hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide.

How it has been given to people: no human use on record.

What to know before reading a dose

  • No human data. It has not been given to people in any published or registered study, so no dose for people has been tested.
  • It is a small molecule, not a peptide, even though Health Canada's seizure list groups a product of this name with injectable peptide drugs [11].
  • Do not assume it works by mouth. The lab that developed it reports that it lacks oral bioavailability, and its mouse studies injected it into the abdomen [1], [3].
  • Not approved in the US or Canada. Health Canada has seized a product sold under this name as an unauthorized drug [11].
  • The mouse dose was 50 mg per kg twice a day by injection. That is an animal dose and cannot be read across as a dose for a person.

What the evidence shows

Each finding is tagged by the kind of study it comes from. Human trials are listed first.

Animal study

In mice it increased oxidative muscle fibers and let the animals run longer. [1]

Animal study

The endurance test gave mice 50 mg per kg by injection into the abdomen twice a day for 7 days. [1]

Animal study

The same paper reports no overt toxicity in mice at that dose over 10 days. [1]

Animal study

In obese mice it reduced obesity and improved insulin sensitivity. [2]

Animal study

The lab that made it reports that it lacks oral bioavailability, and describes a different compound, SLU-PP-915, as the orally active one. [3]

Animal study

In a mouse model of heart failure from pressure overload it improved ejection fraction and survival. [4]

Animal study

In 21-month-old mice treated for 8 weeks it reversed age-related kidney changes such as albumin in the urine. [5]

Lab study

The only human material found: muscle cells grown from biopsies of inactive women were treated in the dish. Nobody was given the compound. [6]

Lab study

Anti-doping researchers have mapped its breakdown products so that use by athletes can be detected. [7]

Side effects and warnings

No side effect data from human studies was found for SLU-PP-332. That is a gap in the research, not a sign that it is safe.

SLU-PP-332 has no approved label in the US or Canada for this use, so there is no official list of who should not use it, no interaction list and no missed-dose rule.

Storage

Keep an unmixed vial the way its label says. Once it is mixed, keep it in the fridge, do not freeze it, and write the mixing date on the vial.

SLU-PP-332 dosage questions

Is SLU-PP-332 approved in the US?

Not FDA approved. Drugs@FDA has no application for it and no clinical trial is registered.

Is SLU-PP-332 authorized in Canada?

No product is in the Health Canada Drug Product Database. A product labelled SLU-PP-332 was among unauthorized products Health Canada seized.

What human dosing data is there for SLU-PP-332?

No human data. It has not been given to people in any published or registered study, so no dose for people has been tested.

Sources

Each one was opened on 10 Oct 2026 and matched to the line it supports.

  1. Billon C et al. Synthetic ERRalpha/beta/gamma Agonist Induces an ERRalpha-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol 2023. PubMed 36988910.
  2. Billon C et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther 2024. PubMed 37739806.
  3. Billon C et al. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. J Pharmacol Exp Ther 2026. PubMed 41421047.
  4. Xu W et al. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation 2024. PubMed 37961903.
  5. Wang XX et al. Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney. Am J Pathol 2023. PubMed 37717940.
  6. Bonanni R et al. Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study. Front Physiol 2025. PubMed 40692696.
  7. Moller T et al. In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential. Rapid Commun Mass Spectrom 2026. PubMed 41588687.
  8. ClinicalTrials.gov searches for SLU-PP-332 and SLU-PP (0 studies) clinicaltrials.gov.
  9. Drugs@FDA via openFDA: search for SLU-PP-332 (no match) api.fda.gov.
  10. Health Canada Drug Product Database: ingredient searches for SLU and SLU-PP-332 (no match) health-products.canada.ca.
  11. Health Canada public advisory: Unauthorized health products sold online and seized at Rize Fitness may pose serious health risks (2025-12-24) recalls-rappels.canada.ca.
  12. FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (PDF, updated May 14, 2026) fda.gov.

Looked for and not found

  • Any study in people. PubMed returned 10 records for SLU-PP-332 and none is a clinical trial, and ClinicalTrials.gov has no registered study [8].
  • A human dose, a human half-life, or human side effects. None exists in the sources found.
  • No approved label anywhere, so no official contraindications, interaction list, missed-dose rule or storage instructions.
  • The mouse dose in the obesity study [2]. Its full text could not be downloaded from PubMed Central, and the abstract gives no dose.
  • Its standing with WADA. The compound is not named on the Prohibited List page; whether a general class covers it was not determined.

Change log

10 Oct 2026Page published. 12 sources checked. No dose chart, because no human dose exists.

Related

Retatrutide dosageTirzepatide dosageSemaglutide dosageCagrilintide dosageAOD-9604 dosageWhat SLU-PP-332 isWeight loss and metabolicPeptide dosage chartDosage calculator

DosageFacts is an information site. It is not medical advice. Talk to a licensed professional before using any medication.